SCHEMBL846959

SCHEMBL846959

Cc1ccc(C(=O)CCc2ccc(Cl)nc2)c(Nc2ccccc2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.40
▸ STAT6 P42226 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PDE4B Q07343 4/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP2C9 P11712 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ HAT1 O14929 2/20 0.36
▸ EP300 Q09472 2/20 0.36
▸ IGF1R P08069 1/20 0.36
▸ ZAP70 P43403 1/20 0.36
▸ SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847744 0.87 STAT6 (0.39) STAT6PDE4BMAPK8IGF1RZAP70
SCHEMBL846971 0.86 STAT6 (0.38) STAT6PDE4BMAPK8SMN1; SMN2IGF1R
SCHEMBL847717 0.85 KMT2A (0.42) STAT6ALDH1A1KMT2APDE4BMAPK8
SCHEMBL848421 0.85 FAAH (0.41) STAT6KMT2ANPC1RAB9A
SCHEMBL847737 0.85 PDE4B (0.38) STAT6PDE4BMAPK8NAMPTIGF1R
SCHEMBL849127 0.84 STAT6 (0.37) FFAR1STAT6PDE4BMAPK8IGF1R
SCHEMBL848924 0.83 CYP1A2 (0.44) ALDH1A1CYP2C9NAMPT
SCHEMBL3637778 0.79 GAA (0.38) ALDH1A1KMT2ASMN1; SMN2LMNA
SCHEMBL847911 0.77 HDAC3 (0.38) ALDH1A1KMT2AMAPK8NPC1RAB9A
SCHEMBL846972 0.76 MAPT (0.36) STAT6ALDH1A1KMT2APDE4BMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163906-B2 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO, LLC (US) 2012-04-24 — — US disclosed
EP-2148862-B1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-03-28 — — EP disclosed
EP-2148862-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. Hoffmann-Roche AG (CH) 2010-02-03 — — EP disclosed
WO-2009015917-A2 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — WO disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 — — WO disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 FFAR1 3150/4885STAT6 611/4885ALDH1A1 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback